News

Jatin Panwar starts as tenured assistant Professor at IIT Delhi

Published:30.05.24 — Starting May 2024, after four and a half years at LBMM, Jatin has successfully taken the next career step, now leading a group at IIT Delhi!

Jan.2024, LBMM founds second startup TheraMe!

Published:30.05.24 — After founding the antibody discovery company Velabs Therapeutics in 2017 (now operating as Veraxa Biotech), LBMM now has a second spinoff: TheraMe! – a startup bringing microfluidic technology for personalized cancer therapy into the clinic.

Jan.2024, LBMM has been awarded with a BRIDGE Proof-of-Concept grant!

Published:30.05.24 — The lab has been very active in the field of antibody discovery for more than a decade, and hence it is time for droplet microfluidic antibody discovery 2.0.

Congrats to Dr. Jatin Panwar for the eSeed award!

Published:15.11.21 — Dr. Jatin Panwar and Prof. Christoph Merten of LBMM in association with Till Ryser and Prof. Carlotta Guiducci of CLSI recently received the eSeed award for their proposal to develop an integrated microfluidics platform capable of deterministic encapsulation of cells in droplets for high-throughput biomedical screens.

LBMM awarded by a PHRT Grant

Published:01.11.21 — The laboratory of Biomedical Microfluidics (LBMM) was awarded with a highly selective PHRT grant for the project "Second-generation microfluidic drug testing on solid tumor biopsies for guiding clinical therapy". This 2-year project starts in April 2022 and aims at the development of second generation screening platforms, providing highly multiplexed transcriptomic readouts for hundreds of possible treatment conditions. A second aim is the development of an industry prototype for use in clinical settings, that can be operated by non-specialists.